Imbed Biosciences news

Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned Federal Contractor with fourteen years of flawless performance, jointly announced today that Imbed’s Microlyte® Matrix wound dressing portfolio has been added to Spartan Medical’s VA IDIQ Contract with the U.S. Department of Veteran Affairs (VA). The IDIQ contract, which i

Imbed Biosciences, Inc. announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command’s (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract was awarded through Medical Technology Enterprise Consortium (MTEC) for prototype solutions t

Imbed Biosciences is proud to announce that research conducted using Microlyte Matrix and Microlyte Surgical will be presented in a panel discussion at SAWC, a national wound healing conference.

Imbed Biosciences announced today that clinical results documenting the use of its products, Microlyte® Matrix and Microlyte® SURGICAL, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV from October 29th to 31st, 2021. SAWC is the natio

Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection.  Results will be published in the October issue of WOUNDS, a widely read, peer-reviewed journal in wound care and research.<